Literature DB >> 17490913

Second-generation endometrial ablation treatment: Novasure.

Marlies Y Bongers1.   

Abstract

The Novasure endometrial ablation system consists of a single-use device and a radiofrequency controller. It is a three-dimensional, triangular-shaped bipolar ablation device. The generator functions at 500 kHz and has a power cut-off limit set at a tissue impedance of 50 Ohms. The self-terminating procedure is based on tissue impedance or time. A cavity assessment system works to detect perforations in the uterine cavity. No pretreatment is necessary. Randomized controlled trials have shown that the Novasure system has an amenorrhoea rate of 44-56% at 1-year follow-up, and the 5-year results of a randomized trial will be published shortly. Prospective observational studies show even higher amenorrhoea rates of up to 58-75% up to 5-year follow-up. Hysterectomy rates in the prospective trial were very low (4%). In summary, the Novasure endometrial ablation system is an effective second-generation ablation technique, resulting in a high percentage of amenorrhoea.

Entities:  

Mesh:

Year:  2007        PMID: 17490913     DOI: 10.1016/j.bpobgyn.2007.03.024

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  3 in total

Review 1.  Antenna Designs for Microwave Tissue Ablation.

Authors:  Hojjatollah Fallahi; Punit Prakash
Journal:  Crit Rev Biomed Eng       Date:  2018

2.  Cost effectiveness of endometrial ablation with the NovaSure(®) system versus other global ablation modalities and hysterectomy for treatment of abnormal uterine bleeding: US commercial and Medicaid payer perspectives.

Authors:  Jeffrey D Miller; Gregory M Lenhart; Machaon M Bonafede; Cindy M Basinski; Andrea S Lukes; Kathleen A Troeger
Journal:  Int J Womens Health       Date:  2015-01-06

3.  Does the radiofrequency impedance-controlled endometrial ablation have any morphologic effects on uterine leiomyomata? Report of 3 cases.

Authors:  Oluwole Fadare; Sa A Wang; Idris L Renshaw
Journal:  Diagn Pathol       Date:  2008-07-01       Impact factor: 2.644

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.